نتایج جستجو برای: linagliptin
تعداد نتایج: 506 فیلتر نتایج به سال:
INTRODUCTION Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the management of patients with type 2 diabetes mellitus (T2DM) and renal impairment (RI). A systematic literature review was performed to compare the efficacy and safety of DPP-4 inhibitors in patients with T2DM and RI. METHODS We searched EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials (cut-off...
12 Background: In studying the therapeutic 13 evidence of innovative drug treatments, 14 increasing attention is being devoted to 15 differentiating between results that indicate no 16 significant differences among the treatments 17 under examination (‘‘no proof of difference’’) 18 and results that demonstrate the therapeutic 19 equivalence among the treatments (‘‘proof of no 20 difference’’). ...
INTRODUCTION When first line therapy with metformin is insufficient for patients with type 2 diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and safety of adjunctive antidiabetic agents in patients with inadequately controlled T2D on metformin alone. MATERIALS AND METHODS A search of MEDLINE and CENTRAL, clinicaltrials.gov, regulatory websites was performed...
Objectives: We aimed to investigate the neuroprotective effects of linagliptin in an vitro 6-hydroxydopamine (6-OHDA) Parkinson’s disease model. Methods: 6-OHDA (200 µM) were administered SH-SY5Y cells for 24 h induce model vitro. Cells treated with (1, 10, 50 and 100 nM) 30 minutes before administration. Cell viability was examined by 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید